http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Sun, 09 Aug 2026 20:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Innovent+Biologics+and+Daiichi+Sankyo+Enter+Exclusive+Agreement+for+VANFLYTA%C2%AE+Commercialization+in+China/26892848.html <div class="xn-content"> <ul type="disc"><li>Collaboration to accelerate access to Vanflyta^® for patients with newly diagnosed <i>FLT3</i>-ITD positive AML</li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and <location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 9, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> (01801.HK) and Daiichi Sankyo (TSE: 4568), have entered into an exclusive agreement for the commercialization of Vanflyta® (quizartinib) in <location value="LC/cn" idsrc="xmltag.org" >China</location>.</p> <p>Under the terms of the agreement, Daiichi Sankyo will be responsible for the development, manufacturing and supply of Vanflyta^® while <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics</span> holds sole commercialization rights for Vanflyta^® in <location value="LC/cn" idsrc="xmltag.org" >China</location>, leading market promotion.</p><p>VANFLYTA http://www.streetinsider.com/Press+Releases/Innovent+Biologics+and+Daiichi+Sankyo+Enter+Exclusive+Agreement+for+VANFLYTA%C2%AE+Commercialization+in+China/26892848.html Sun, 09 Aug 2026 20:00:00 -0400 1801 4568 6IB A.17568957 A.22847412 A.33615634 IVBIY O.03960636 O.04889877 O.07116439 O.39140405 http://www.streetinsider.com/Press+Releases/Innovent+Biologics+and+Daiichi+Sankyo+Enter+Exclusive+Agreement+for+VANFLYTA%C2%AE+Commercialization+in+China/26892848.html <div class="xn-content"> <ul type="disc"><li>Collaboration to accelerate access to Vanflyta^® for patients with newly diagnosed <i>FLT3</i>-ITD positive AML</li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and <location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 9, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> (01801.HK) and Daiichi Sankyo (TSE: 4568), have entered into an exclusive agreement for the commercialization of Vanflyta® (quizartinib) in <location value="LC/cn" idsrc="xmltag.org" >China</location>.</p> <p>Under the terms of the agreement, Daiichi Sankyo will be responsible for the development, manufacturing and supply of Vanflyta^® while <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics</span> holds sole commercialization rights for Vanflyta^® in <location value="LC/cn" idsrc="xmltag.org" >China</location>, leading market promotion.</p><p>VANFLYTA http://www.streetinsider.com/Press+Releases/Innovent+Biologics+and+Daiichi+Sankyo+Enter+Exclusive+Agreement+for+VANFLYTA%C2%AE+Commercialization+in+China/26892848.html Sun, 09 Aug 2026 20:00:00 -0400 1801 4568 6IB A.17568957 A.22847412 A.33615634 IVBIY O.03960636 O.04889877 O.07116439 O.39140405 http://www.streetinsider.com/Press+Releases/Innovent+Biologics+and+Daiichi+Sankyo+Enter+Exclusive+Agreement+for+VANFLYTA%C2%AE+Commercialization+in+China/26892848.html <div class="xn-content"> <ul type="disc"><li>Collaboration to accelerate access to Vanflyta^® for patients with newly diagnosed <i>FLT3</i>-ITD positive AML</li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and <location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 9, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> (01801.HK) and Daiichi Sankyo (TSE: 4568), have entered into an exclusive agreement for the commercialization of Vanflyta® (quizartinib) in <location value="LC/cn" idsrc="xmltag.org" >China</location>.</p> <p>Under the terms of the agreement, Daiichi Sankyo will be responsible for the development, manufacturing and supply of Vanflyta^® while <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics</span> holds sole commercialization rights for Vanflyta^® in <location value="LC/cn" idsrc="xmltag.org" >China</location>, leading market promotion.</p><p>VANFLYTA http://www.streetinsider.com/Press+Releases/Innovent+Biologics+and+Daiichi+Sankyo+Enter+Exclusive+Agreement+for+VANFLYTA%C2%AE+Commercialization+in+China/26892848.html Sun, 09 Aug 2026 20:00:00 -0400 1801 4568 6IB A.17568957 A.22847412 A.33615634 IVBIY O.03960636 O.04889877 O.07116439 O.39140405 http://www.streetinsider.com/Press+Releases/Innovent+Biologics+and+Daiichi+Sankyo+Enter+Exclusive+Agreement+for+VANFLYTA%C2%AE+Commercialization+in+China/26892848.html <div class="xn-content"> <ul type="disc"><li>Collaboration to accelerate access to Vanflyta^® for patients with newly diagnosed <i>FLT3</i>-ITD positive AML</li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and <location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 9, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> (01801.HK) and Daiichi Sankyo (TSE: 4568), have entered into an exclusive agreement for the commercialization of Vanflyta® (quizartinib) in <location value="LC/cn" idsrc="xmltag.org" >China</location>.</p> <p>Under the terms of the agreement, Daiichi Sankyo will be responsible for the development, manufacturing and supply of Vanflyta^® while <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics</span> holds sole commercialization rights for Vanflyta^® in <location value="LC/cn" idsrc="xmltag.org" >China</location>, leading market promotion.</p><p>VANFLYTA http://www.streetinsider.com/Press+Releases/Innovent+Biologics+and+Daiichi+Sankyo+Enter+Exclusive+Agreement+for+VANFLYTA%C2%AE+Commercialization+in+China/26892848.html Sun, 09 Aug 2026 20:00:00 -0400 1801 4568 6IB A.17568957 A.22847412 A.33615634 IVBIY O.03960636 O.04889877 O.07116439 O.39140405 http://www.streetinsider.com/Press+Releases/Innovent+Biologics+and+Daiichi+Sankyo+Enter+Exclusive+Agreement+for+VANFLYTA%C2%AE+Commercialization+in+China/26892848.html <div class="xn-content"> <ul type="disc"><li>Collaboration to accelerate access to Vanflyta^® for patients with newly diagnosed <i>FLT3</i>-ITD positive AML</li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and <location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 9, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> (01801.HK) and Daiichi Sankyo (TSE: 4568), have entered into an exclusive agreement for the commercialization of Vanflyta® (quizartinib) in <location value="LC/cn" idsrc="xmltag.org" >China</location>.</p> <p>Under the terms of the agreement, Daiichi Sankyo will be responsible for the development, manufacturing and supply of Vanflyta^® while <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics</span> holds sole commercialization rights for Vanflyta^® in <location value="LC/cn" idsrc="xmltag.org" >China</location>, leading market promotion.</p><p>VANFLYTA http://www.streetinsider.com/Press+Releases/Innovent+Biologics+and+Daiichi+Sankyo+Enter+Exclusive+Agreement+for+VANFLYTA%C2%AE+Commercialization+in+China/26892848.html Sun, 09 Aug 2026 20:00:00 -0400 1801 4568 6IB A.17568957 A.22847412 A.33615634 IVBIY O.03960636 O.04889877 O.07116439 O.39140405 http://www.streetinsider.com/Press+Releases/Innovent+Biologics+and+Daiichi+Sankyo+Enter+Exclusive+Agreement+for+VANFLYTA%C2%AE+Commercialization+in+China/26892848.html <div class="xn-content"> <ul type="disc"><li>Collaboration to accelerate access to Vanflyta^® for patients with newly diagnosed <i>FLT3</i>-ITD positive AML</li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and <location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 9, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> (01801.HK) and Daiichi Sankyo (TSE: 4568), have entered into an exclusive agreement for the commercialization of Vanflyta® (quizartinib) in <location value="LC/cn" idsrc="xmltag.org" >China</location>.</p> <p>Under the terms of the agreement, Daiichi Sankyo will be responsible for the development, manufacturing and supply of Vanflyta^® while <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics</span> holds sole commercialization rights for Vanflyta^® in <location value="LC/cn" idsrc="xmltag.org" >China</location>, leading market promotion.</p><p>VANFLYTA http://www.streetinsider.com/Press+Releases/Innovent+Biologics+and+Daiichi+Sankyo+Enter+Exclusive+Agreement+for+VANFLYTA%C2%AE+Commercialization+in+China/26892848.html Sun, 09 Aug 2026 20:00:00 -0400 1801 4568 6IB A.17568957 A.22847412 A.33615634 IVBIY O.03960636 O.04889877 O.07116439 O.39140405 http://www.streetinsider.com/Press+Releases/Innovent+Biologics+and+Daiichi+Sankyo+Enter+Exclusive+Agreement+for+VANFLYTA%C2%AE+Commercialization+in+China/26892848.html <div class="xn-content"> <ul type="disc"><li>Collaboration to accelerate access to Vanflyta^® for patients with newly diagnosed <i>FLT3</i>-ITD positive AML</li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and <location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 9, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> (01801.HK) and Daiichi Sankyo (TSE: 4568), have entered into an exclusive agreement for the commercialization of Vanflyta® (quizartinib) in <location value="LC/cn" idsrc="xmltag.org" >China</location>.</p> <p>Under the terms of the agreement, Daiichi Sankyo will be responsible for the development, manufacturing and supply of Vanflyta^® while <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics</span> holds sole commercialization rights for Vanflyta^® in <location value="LC/cn" idsrc="xmltag.org" >China</location>, leading market promotion.</p><p>VANFLYTA http://www.streetinsider.com/Press+Releases/Innovent+Biologics+and+Daiichi+Sankyo+Enter+Exclusive+Agreement+for+VANFLYTA%C2%AE+Commercialization+in+China/26892848.html Sun, 09 Aug 2026 20:00:00 -0400 1801 4568 6IB A.17568957 A.22847412 A.33615634 IVBIY O.03960636 O.04889877 O.07116439 O.39140405 http://www.streetinsider.com/Press+Releases/Innovent+Biologics+and+Daiichi+Sankyo+Enter+Exclusive+Agreement+for+VANFLYTA%C2%AE+Commercialization+in+China/26892848.html <div class="xn-content"> <ul type="disc"><li>Collaboration to accelerate access to Vanflyta^® for patients with newly diagnosed <i>FLT3</i>-ITD positive AML</li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and <location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 9, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> (01801.HK) and Daiichi Sankyo (TSE: 4568), have entered into an exclusive agreement for the commercialization of Vanflyta® (quizartinib) in <location value="LC/cn" idsrc="xmltag.org" >China</location>.</p> <p>Under the terms of the agreement, Daiichi Sankyo will be responsible for the development, manufacturing and supply of Vanflyta^® while <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics</span> holds sole commercialization rights for Vanflyta^® in <location value="LC/cn" idsrc="xmltag.org" >China</location>, leading market promotion.</p><p>VANFLYTA http://www.streetinsider.com/Press+Releases/Innovent+Biologics+and+Daiichi+Sankyo+Enter+Exclusive+Agreement+for+VANFLYTA%C2%AE+Commercialization+in+China/26892848.html Sun, 09 Aug 2026 20:00:00 -0400 1801 4568 6IB A.17568957 A.22847412 A.33615634 IVBIY O.03960636 O.04889877 O.07116439 O.39140405 http://www.streetinsider.com/Press+Releases/Innovent+Biologics+and+Daiichi+Sankyo+Enter+Exclusive+Agreement+for+VANFLYTA%C2%AE+Commercialization+in+China/26892848.html <div class="xn-content"> <ul type="disc"><li>Collaboration to accelerate access to Vanflyta^® for patients with newly diagnosed <i>FLT3</i>-ITD positive AML</li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and <location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 9, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> (01801.HK) and Daiichi Sankyo (TSE: 4568), have entered into an exclusive agreement for the commercialization of Vanflyta® (quizartinib) in <location value="LC/cn" idsrc="xmltag.org" >China</location>.</p> <p>Under the terms of the agreement, Daiichi Sankyo will be responsible for the development, manufacturing and supply of Vanflyta^® while <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics</span> holds sole commercialization rights for Vanflyta^® in <location value="LC/cn" idsrc="xmltag.org" >China</location>, leading market promotion.</p><p>VANFLYTA http://www.streetinsider.com/Press+Releases/Innovent+Biologics+and+Daiichi+Sankyo+Enter+Exclusive+Agreement+for+VANFLYTA%C2%AE+Commercialization+in+China/26892848.html Sun, 09 Aug 2026 20:00:00 -0400 1801 4568 6IB A.17568957 A.22847412 A.33615634 IVBIY O.03960636 O.04889877 O.07116439 O.39140405 http://www.streetinsider.com/Press+Releases/Innovent+Biologics+and+Daiichi+Sankyo+Enter+Exclusive+Agreement+for+VANFLYTA%C2%AE+Commercialization+in+China/26892848.html <div class="xn-content"> <ul type="disc"><li>Collaboration to accelerate access to Vanflyta^® for patients with newly diagnosed <i>FLT3</i>-ITD positive AML</li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and <location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 9, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> (01801.HK) and Daiichi Sankyo (TSE: 4568), have entered into an exclusive agreement for the commercialization of Vanflyta® (quizartinib) in <location value="LC/cn" idsrc="xmltag.org" >China</location>.</p> <p>Under the terms of the agreement, Daiichi Sankyo will be responsible for the development, manufacturing and supply of Vanflyta^® while <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics</span> holds sole commercialization rights for Vanflyta^® in <location value="LC/cn" idsrc="xmltag.org" >China</location>, leading market promotion.</p><p>VANFLYTA http://www.streetinsider.com/Press+Releases/Innovent+Biologics+and+Daiichi+Sankyo+Enter+Exclusive+Agreement+for+VANFLYTA%C2%AE+Commercialization+in+China/26892848.html Sun, 09 Aug 2026 20:00:00 -0400 1801 4568 6IB A.17568957 A.22847412 A.33615634 IVBIY O.03960636 O.04889877 O.07116439 O.39140405 http://www.streetinsider.com/Press+Releases/Innovent+Biologics+and+Daiichi+Sankyo+Enter+Exclusive+Agreement+for+VANFLYTA%C2%AE+Commercialization+in+China/26892848.html <div class="xn-content"> <ul type="disc"><li>Collaboration to accelerate access to Vanflyta^® for patients with newly diagnosed <i>FLT3</i>-ITD positive AML</li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and <location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 9, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> (01801.HK) and Daiichi Sankyo (TSE: 4568), have entered into an exclusive agreement for the commercialization of Vanflyta® (quizartinib) in <location value="LC/cn" idsrc="xmltag.org" >China</location>.</p> <p>Under the terms of the agreement, Daiichi Sankyo will be responsible for the development, manufacturing and supply of Vanflyta^® while <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics</span> holds sole commercialization rights for Vanflyta^® in <location value="LC/cn" idsrc="xmltag.org" >China</location>, leading market promotion.</p><p>VANFLYTA http://www.streetinsider.com/Press+Releases/Innovent+Biologics+and+Daiichi+Sankyo+Enter+Exclusive+Agreement+for+VANFLYTA%C2%AE+Commercialization+in+China/26892848.html Sun, 09 Aug 2026 20:00:00 -0400 1801 4568 6IB A.17568957 A.22847412 A.33615634 IVBIY O.03960636 O.04889877 O.07116439 O.39140405 http://www.streetinsider.com/PRNewswire/Innovent+Biologics+and+Daiichi+Sankyo+Enter+Exclusive+Agreement+for+VANFLYTA%C2%AE+Commercialization+in+China/26892848.html <div class="xn-content"> <ul type="disc"><li>Collaboration to accelerate access to Vanflyta^® for patients with newly diagnosed <i>FLT3</i>-ITD positive AML</li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and <location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 9, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> (01801.HK) and Daiichi Sankyo (TSE: 4568), have entered into an exclusive agreement for the commercialization of Vanflyta® (quizartinib) in <location value="LC/cn" idsrc="xmltag.org" >China</location>.</p> <p>Under the terms of the agreement, Daiichi Sankyo will be responsible for the development, manufacturing and supply of Vanflyta^® while <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics</span> holds sole commercialization rights for Vanflyta^® in <location value="LC/cn" idsrc="xmltag.org" >China</location>, leading market promotion.</p><p>VANFLYTA http://www.streetinsider.com/PRNewswire/Innovent+Biologics+and+Daiichi+Sankyo+Enter+Exclusive+Agreement+for+VANFLYTA%C2%AE+Commercialization+in+China/26892848.html Sun, 09 Aug 2026 20:00:00 -0400 1801 4568 6IB A.17568957 A.22847412 A.33615634 IVBIY O.03960636 O.04889877 O.07116439 O.39140405 http://www.streetinsider.com/PRNewswire/Innovent+Biologics+and+Daiichi+Sankyo+Enter+Exclusive+Agreement+for+VANFLYTA%C2%AE+Commercialization+in+China/26892848.html <div class="xn-content"> <ul type="disc"><li>Collaboration to accelerate access to Vanflyta^® for patients with newly diagnosed <i>FLT3</i>-ITD positive AML</li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and <location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 9, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> (01801.HK) and Daiichi Sankyo (TSE: 4568), have entered into an exclusive agreement for the commercialization of Vanflyta® (quizartinib) in <location value="LC/cn" idsrc="xmltag.org" >China</location>.</p> <p>Under the terms of the agreement, Daiichi Sankyo will be responsible for the development, manufacturing and supply of Vanflyta^® while <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics</span> holds sole commercialization rights for Vanflyta^® in <location value="LC/cn" idsrc="xmltag.org" >China</location>, leading market promotion.</p><p>VANFLYTA http://www.streetinsider.com/PRNewswire/Innovent+Biologics+and+Daiichi+Sankyo+Enter+Exclusive+Agreement+for+VANFLYTA%C2%AE+Commercialization+in+China/26892848.html Sun, 09 Aug 2026 20:00:00 -0400 1801 4568 6IB A.17568957 A.22847412 A.33615634 IVBIY O.03960636 O.04889877 O.07116439 O.39140405 http://www.streetinsider.com/PRNewswire/Innovent+Biologics+and+Daiichi+Sankyo+Enter+Exclusive+Agreement+for+VANFLYTA%C2%AE+Commercialization+in+China/26892848.html <div class="xn-content"> <ul type="disc"><li>Collaboration to accelerate access to Vanflyta^® for patients with newly diagnosed <i>FLT3</i>-ITD positive AML</li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and <location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 9, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> (01801.HK) and Daiichi Sankyo (TSE: 4568), have entered into an exclusive agreement for the commercialization of Vanflyta® (quizartinib) in <location value="LC/cn" idsrc="xmltag.org" >China</location>.</p> <p>Under the terms of the agreement, Daiichi Sankyo will be responsible for the development, manufacturing and supply of Vanflyta^® while <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics</span> holds sole commercialization rights for Vanflyta^® in <location value="LC/cn" idsrc="xmltag.org" >China</location>, leading market promotion.</p><p>VANFLYTA http://www.streetinsider.com/PRNewswire/Innovent+Biologics+and+Daiichi+Sankyo+Enter+Exclusive+Agreement+for+VANFLYTA%C2%AE+Commercialization+in+China/26892848.html Sun, 09 Aug 2026 20:00:00 -0400 1801 4568 6IB A.17568957 A.22847412 A.33615634 IVBIY O.03960636 O.04889877 O.07116439 O.39140405 http://www.streetinsider.com/PRNewswire/Innovent+Biologics+and+Daiichi+Sankyo+Enter+Exclusive+Agreement+for+VANFLYTA%C2%AE+Commercialization+in+China/26892848.html <div class="xn-content"> <ul type="disc"><li>Collaboration to accelerate access to Vanflyta^® for patients with newly diagnosed <i>FLT3</i>-ITD positive AML</li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and <location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 9, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> (01801.HK) and Daiichi Sankyo (TSE: 4568), have entered into an exclusive agreement for the commercialization of Vanflyta® (quizartinib) in <location value="LC/cn" idsrc="xmltag.org" >China</location>.</p> <p>Under the terms of the agreement, Daiichi Sankyo will be responsible for the development, manufacturing and supply of Vanflyta^® while <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics</span> holds sole commercialization rights for Vanflyta^® in <location value="LC/cn" idsrc="xmltag.org" >China</location>, leading market promotion.</p><p>VANFLYTA http://www.streetinsider.com/PRNewswire/Innovent+Biologics+and+Daiichi+Sankyo+Enter+Exclusive+Agreement+for+VANFLYTA%C2%AE+Commercialization+in+China/26892848.html Sun, 09 Aug 2026 20:00:00 -0400 1801 4568 6IB A.17568957 A.22847412 A.33615634 IVBIY O.03960636 O.04889877 O.07116439 O.39140405 http://www.streetinsider.com/PRNewswire/Innovent+Biologics+and+Daiichi+Sankyo+Enter+Exclusive+Agreement+for+VANFLYTA%C2%AE+Commercialization+in+China/26892848.html <div class="xn-content"> <ul type="disc"><li>Collaboration to accelerate access to Vanflyta^® for patients with newly diagnosed <i>FLT3</i>-ITD positive AML</li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and <location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 9, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> (01801.HK) and Daiichi Sankyo (TSE: 4568), have entered into an exclusive agreement for the commercialization of Vanflyta® (quizartinib) in <location value="LC/cn" idsrc="xmltag.org" >China</location>.</p> <p>Under the terms of the agreement, Daiichi Sankyo will be responsible for the development, manufacturing and supply of Vanflyta^® while <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics</span> holds sole commercialization rights for Vanflyta^® in <location value="LC/cn" idsrc="xmltag.org" >China</location>, leading market promotion.</p><p>VANFLYTA http://www.streetinsider.com/PRNewswire/Innovent+Biologics+and+Daiichi+Sankyo+Enter+Exclusive+Agreement+for+VANFLYTA%C2%AE+Commercialization+in+China/26892848.html Sun, 09 Aug 2026 20:00:00 -0400 1801 4568 6IB A.17568957 A.22847412 A.33615634 IVBIY O.03960636 O.04889877 O.07116439 O.39140405 http://www.streetinsider.com/PRNewswire/Innovent+Biologics+and+Daiichi+Sankyo+Enter+Exclusive+Agreement+for+VANFLYTA%C2%AE+Commercialization+in+China/26892848.html <div class="xn-content"> <ul type="disc"><li>Collaboration to accelerate access to Vanflyta^® for patients with newly diagnosed <i>FLT3</i>-ITD positive AML</li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and <location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 9, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> (01801.HK) and Daiichi Sankyo (TSE: 4568), have entered into an exclusive agreement for the commercialization of Vanflyta® (quizartinib) in <location value="LC/cn" idsrc="xmltag.org" >China</location>.</p> <p>Under the terms of the agreement, Daiichi Sankyo will be responsible for the development, manufacturing and supply of Vanflyta^® while <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics</span> holds sole commercialization rights for Vanflyta^® in <location value="LC/cn" idsrc="xmltag.org" >China</location>, leading market promotion.</p><p>VANFLYTA http://www.streetinsider.com/PRNewswire/Innovent+Biologics+and+Daiichi+Sankyo+Enter+Exclusive+Agreement+for+VANFLYTA%C2%AE+Commercialization+in+China/26892848.html Sun, 09 Aug 2026 20:00:00 -0400 1801 4568 6IB A.17568957 A.22847412 A.33615634 IVBIY O.03960636 O.04889877 O.07116439 O.39140405 http://www.streetinsider.com/PRNewswire/Innovent+Biologics+and+Daiichi+Sankyo+Enter+Exclusive+Agreement+for+VANFLYTA%C2%AE+Commercialization+in+China/26892848.html <div class="xn-content"> <ul type="disc"><li>Collaboration to accelerate access to Vanflyta^® for patients with newly diagnosed <i>FLT3</i>-ITD positive AML</li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and <location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 9, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> (01801.HK) and Daiichi Sankyo (TSE: 4568), have entered into an exclusive agreement for the commercialization of Vanflyta® (quizartinib) in <location value="LC/cn" idsrc="xmltag.org" >China</location>.</p> <p>Under the terms of the agreement, Daiichi Sankyo will be responsible for the development, manufacturing and supply of Vanflyta^® while <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics</span> holds sole commercialization rights for Vanflyta^® in <location value="LC/cn" idsrc="xmltag.org" >China</location>, leading market promotion.</p><p>VANFLYTA http://www.streetinsider.com/PRNewswire/Innovent+Biologics+and+Daiichi+Sankyo+Enter+Exclusive+Agreement+for+VANFLYTA%C2%AE+Commercialization+in+China/26892848.html Sun, 09 Aug 2026 20:00:00 -0400 1801 4568 6IB A.17568957 A.22847412 A.33615634 IVBIY O.03960636 O.04889877 O.07116439 O.39140405 http://www.streetinsider.com/PRNewswire/Innovent+Biologics+and+Daiichi+Sankyo+Enter+Exclusive+Agreement+for+VANFLYTA%C2%AE+Commercialization+in+China/26892848.html <div class="xn-content"> <ul type="disc"><li>Collaboration to accelerate access to Vanflyta^® for patients with newly diagnosed <i>FLT3</i>-ITD positive AML</li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and <location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 9, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> (01801.HK) and Daiichi Sankyo (TSE: 4568), have entered into an exclusive agreement for the commercialization of Vanflyta® (quizartinib) in <location value="LC/cn" idsrc="xmltag.org" >China</location>.</p> <p>Under the terms of the agreement, Daiichi Sankyo will be responsible for the development, manufacturing and supply of Vanflyta^® while <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics</span> holds sole commercialization rights for Vanflyta^® in <location value="LC/cn" idsrc="xmltag.org" >China</location>, leading market promotion.</p><p>VANFLYTA http://www.streetinsider.com/PRNewswire/Innovent+Biologics+and+Daiichi+Sankyo+Enter+Exclusive+Agreement+for+VANFLYTA%C2%AE+Commercialization+in+China/26892848.html Sun, 09 Aug 2026 20:00:00 -0400 1801 4568 6IB A.17568957 A.22847412 A.33615634 IVBIY O.03960636 O.04889877 O.07116439 O.39140405 http://www.streetinsider.com/PRNewswire/Innovent+Biologics+and+Daiichi+Sankyo+Enter+Exclusive+Agreement+for+VANFLYTA%C2%AE+Commercialization+in+China/26892848.html <div class="xn-content"> <ul type="disc"><li>Collaboration to accelerate access to Vanflyta^® for patients with newly diagnosed <i>FLT3</i>-ITD positive AML</li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and <location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 9, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> (01801.HK) and Daiichi Sankyo (TSE: 4568), have entered into an exclusive agreement for the commercialization of Vanflyta® (quizartinib) in <location value="LC/cn" idsrc="xmltag.org" >China</location>.</p> <p>Under the terms of the agreement, Daiichi Sankyo will be responsible for the development, manufacturing and supply of Vanflyta^® while <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics</span> holds sole commercialization rights for Vanflyta^® in <location value="LC/cn" idsrc="xmltag.org" >China</location>, leading market promotion.</p><p>VANFLYTA http://www.streetinsider.com/PRNewswire/Innovent+Biologics+and+Daiichi+Sankyo+Enter+Exclusive+Agreement+for+VANFLYTA%C2%AE+Commercialization+in+China/26892848.html Sun, 09 Aug 2026 20:00:00 -0400 1801 4568 6IB A.17568957 A.22847412 A.33615634 IVBIY O.03960636 O.04889877 O.07116439 O.39140405 http://www.streetinsider.com/PRNewswire/Innovent+Biologics+and+Daiichi+Sankyo+Enter+Exclusive+Agreement+for+VANFLYTA%C2%AE+Commercialization+in+China/26892848.html <div class="xn-content"> <ul type="disc"><li>Collaboration to accelerate access to Vanflyta^® for patients with newly diagnosed <i>FLT3</i>-ITD positive AML</li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and <location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 9, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> (01801.HK) and Daiichi Sankyo (TSE: 4568), have entered into an exclusive agreement for the commercialization of Vanflyta® (quizartinib) in <location value="LC/cn" idsrc="xmltag.org" >China</location>.</p> <p>Under the terms of the agreement, Daiichi Sankyo will be responsible for the development, manufacturing and supply of Vanflyta^® while <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics</span> holds sole commercialization rights for Vanflyta^® in <location value="LC/cn" idsrc="xmltag.org" >China</location>, leading market promotion.</p><p>VANFLYTA http://www.streetinsider.com/PRNewswire/Innovent+Biologics+and+Daiichi+Sankyo+Enter+Exclusive+Agreement+for+VANFLYTA%C2%AE+Commercialization+in+China/26892848.html Sun, 09 Aug 2026 20:00:00 -0400 1801 4568 6IB A.17568957 A.22847412 A.33615634 IVBIY O.03960636 O.04889877 O.07116439 O.39140405 http://www.streetinsider.com/PRNewswire/Innovent+Biologics+and+Daiichi+Sankyo+Enter+Exclusive+Agreement+for+VANFLYTA%C2%AE+Commercialization+in+China/26892848.html <div class="xn-content"> <ul type="disc"><li>Collaboration to accelerate access to Vanflyta^® for patients with newly diagnosed <i>FLT3</i>-ITD positive AML</li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and <location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 9, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> (01801.HK) and Daiichi Sankyo (TSE: 4568), have entered into an exclusive agreement for the commercialization of Vanflyta® (quizartinib) in <location value="LC/cn" idsrc="xmltag.org" >China</location>.</p> <p>Under the terms of the agreement, Daiichi Sankyo will be responsible for the development, manufacturing and supply of Vanflyta^® while <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics</span> holds sole commercialization rights for Vanflyta^® in <location value="LC/cn" idsrc="xmltag.org" >China</location>, leading market promotion.</p><p>VANFLYTA http://www.streetinsider.com/PRNewswire/Innovent+Biologics+and+Daiichi+Sankyo+Enter+Exclusive+Agreement+for+VANFLYTA%C2%AE+Commercialization+in+China/26892848.html Sun, 09 Aug 2026 20:00:00 -0400 1801 4568 6IB A.17568957 A.22847412 A.33615634 IVBIY O.03960636 O.04889877 O.07116439 O.39140405 http://www.streetinsider.com/Press+Releases/Innovent+Announces+First+Patient+Dosed+in+Pivotal+Registrational+Study+of+IBI363TAK-928+%28PD-1IL-2%CE%B1-biased+Bispecific+Fusion+Protein%29+in+Combination+with+Bevacizumab+in+Late-Line+Advanced+Colorectal/26876545.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and <location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 5, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology, and other major diseases, announced that the first patient has been dosed in a pivotal study evaluating IBI363 (Takeda R&amp;D code: TAK-928), a potential first-in-class PD-1/IL-2^α-biased bispecific fusion protein, in combination with bevacizumab versus investigator's choice of therapy, in patients with advanced colorectal cancer (CRC) that is refractory or intolerant to http://www.streetinsider.com/Press+Releases/Innovent+Announces+First+Patient+Dosed+in+Pivotal+Registrational+Study+of+IBI363TAK-928+%28PD-1IL-2%CE%B1-biased+Bispecific+Fusion+Protein%29+in+Combination+with+Bevacizumab+in+Late-Line+Advanced+Colorectal/26876545.html Wed, 05 Aug 2026 20:00:00 -0400 01801 1801 6IB A.06822034 A.21266042 IVBIY O.20026344 O.22928446 O.39140405 http://www.streetinsider.com/Press+Releases/Innovent+Announces+First+Patient+Dosed+in+Pivotal+Registrational+Study+of+IBI363TAK-928+%28PD-1IL-2%CE%B1-biased+Bispecific+Fusion+Protein%29+in+Combination+with+Bevacizumab+in+Late-Line+Advanced+Colorectal/26876545.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and <location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 5, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology, and other major diseases, announced that the first patient has been dosed in a pivotal study evaluating IBI363 (Takeda R&amp;D code: TAK-928), a potential first-in-class PD-1/IL-2^α-biased bispecific fusion protein, in combination with bevacizumab versus investigator's choice of therapy, in patients with advanced colorectal cancer (CRC) that is refractory or intolerant to http://www.streetinsider.com/Press+Releases/Innovent+Announces+First+Patient+Dosed+in+Pivotal+Registrational+Study+of+IBI363TAK-928+%28PD-1IL-2%CE%B1-biased+Bispecific+Fusion+Protein%29+in+Combination+with+Bevacizumab+in+Late-Line+Advanced+Colorectal/26876545.html Wed, 05 Aug 2026 20:00:00 -0400 01801 1801 6IB A.06822034 A.21266042 IVBIY O.20026344 O.22928446 O.39140405 http://www.streetinsider.com/Press+Releases/Innovent+Announces+First+Patient+Dosed+in+Pivotal+Registrational+Study+of+IBI363TAK-928+%28PD-1IL-2%CE%B1-biased+Bispecific+Fusion+Protein%29+in+Combination+with+Bevacizumab+in+Late-Line+Advanced+Colorectal/26876545.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and <location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 5, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology, and other major diseases, announced that the first patient has been dosed in a pivotal study evaluating IBI363 (Takeda R&amp;D code: TAK-928), a potential first-in-class PD-1/IL-2^α-biased bispecific fusion protein, in combination with bevacizumab versus investigator's choice of therapy, in patients with advanced colorectal cancer (CRC) that is refractory or intolerant to http://www.streetinsider.com/Press+Releases/Innovent+Announces+First+Patient+Dosed+in+Pivotal+Registrational+Study+of+IBI363TAK-928+%28PD-1IL-2%CE%B1-biased+Bispecific+Fusion+Protein%29+in+Combination+with+Bevacizumab+in+Late-Line+Advanced+Colorectal/26876545.html Wed, 05 Aug 2026 20:00:00 -0400 01801 1801 6IB A.06822034 A.21266042 IVBIY O.20026344 O.22928446 O.39140405